To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer

Trial Details

NCT ID

NCT06389006

Phase

PHASE2

Sponsor

RemeGen Co., Ltd.

Status

RECRUITING

Cancer Type

HER2 Positive Breast Cancer

Interventions

• Disitamab Vedotin for Injection
• Toripalimab
• Epirubicin
• Cyclophosphamide

Locations (sample)

• Shanghai, Fudan University Shanghai Cancer Center, China|31.22222,121.45806

Key Eligibility Criteria

• Voluntarily agree to participate in the study and sign the informed consent;
• Age ≥18 years old (including the threshold value);
• Histologically confirmed invasive breast cancer with clinical stage T1c-T2(≥2cm)cN1-2M0 or T3cN0-2M0;
• As assessed by the research Center, the subjects can tolerate and plan to undergo radical surgery for breast cancer and have not previously receive…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.